ArticleAnnals of medicine and surgery (2012)2025
Lactate dehydrogenase to albumin ratio as a prognostic indicator for patients with resectable non-small cell lung cancer.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lactate dehydrogenase-to-albumin ratio as a novel prognostic biomarker for 28-day mortality in thoracic trauma: a single-center retrospective cohort study.Turkish journal of medical sciences · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Serum lactate dehydrogenase to albumin ratio (LAR) is a newly discovered indicator that can comprehensively reflect the inflammatory or nutritional status of the body and has been proven to be associated with several diseases. This study aimed to investigate whether a high baseline LAR independently predicts worse prognosis in non-small cell lung cancer (NSCLC) patients undergoing radical surgery. Methods: This study retrospectively reviewed NSCLC patients who received radical surgery between January 2019 and October 2021 in our institution. Then, these patients were further categorized into low LAR and high LAR groups using X-tile software. Both univariate and multivariate logistic regression analyses were utilized to identify independent predictors of disease-free survival (DFS). A paired Results: A total of 233 patients were enrolled in this study. Patients with high baseline LAR had significantly worse DFS ( Conclusion: LAR emerged as a potential prognostic indicator for operable NSCLC patients. Cases with higher baseline LAR levels tend to have a poorer prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.